Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma

An Bras Dermatol. 2016 May-Jun;91(3):368-71. doi: 10.1590/abd1806-4841.20163875.

Abstract

Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.

Publication types

  • Case Reports

MeSH terms

  • Arthritis, Rheumatoid / drug therapy
  • Etanercept / adverse effects*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Lymphoma, T-Cell, Cutaneous / chemically induced*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Male
  • Methotrexate / adverse effects*
  • Middle Aged
  • Orchiectomy
  • Skin Neoplasms / chemically induced*
  • Skin Neoplasms / pathology
  • Testicular Diseases / diagnosis
  • Testicular Diseases / surgery

Substances

  • Immunosuppressive Agents
  • Etanercept
  • Methotrexate